Karin Purshouse

Karin Purshouse

Auto-generated profile, based on publicly available information

Karin Purshouse

MRC Human Genetics Unit, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, United Kingdom

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
PSParker L. Sulkowski
Parker L. Sulkowski
CCChristopher D. Corso
Christopher D. Corso
NRNathaniel D. Robinson
Nathaniel D. Robinson
SSSusan E. Scanlon
Susan E. Scanlon
KPKarin R. Purshouse
Karin R. Purshouse
RBRanjit Bindra
Ranjit Bindra
The oncometabolite 2-hydroxyglutarate renders IDH1/2 mutant cancer cells deficient in homologous recombination and confers vulnerability to synthetic lethal targeting with PARP inhibitors.

13 June 2016 in Oncogene
Verified
Journal Article
Open access
PDF file
LML L da Motta
L L da Motta
ILI Ledaki
I Ledaki
KPK Purshouse
K Purshouse
SHS Haider
S Haider
MBM A De Bastiani
M A De Bastiani
AMA McIntyre
A McIntyre
The availability of bromodomain and extra-terminal inhibitors (BETi) has enabled translational epigenetic studies in cancer. BET proteins regulate transcription by selectively recognizing acetylated lysine residues on chromatin. BETi compete with this process leading to both downregulation and upregulation of gene expression. Hypoxia enables progression of triple negative breast cancer (TNBC), the most aggressive form of breast cancer, partly by driving metabolic adaptation, angiogenesis and metastasis through upregulation of hypoxia-regulated genes (for example, carbonic anhydrase 9 (CA9) and vascular endothelial growth factor A (VEGF-A). Responses to hypoxia can be mediated epigenetically, thus we investigated whether BETi JQ1 could impair the TNBC response induced by hypoxia and exert anti-tumour effects. JQ1 significantly modulated 44% of hypoxia-induced genes, of which two-thirds were downregulated including CA9 and VEGF-A. JQ1 prevented HIF binding to the hypoxia response element in CA9 promoter, but did not alter HIF expression or activity, suggesting some HIF targets are BET-dependent. JQ1 reduced TNBC growth in vitro and in vivo and inhibited xenograft vascularization. These findings identify that BETi dually targets angiogenesis and the hypoxic response, an effective combination at reducing tumour growth in preclinical studies.

12 January 2018 in The FEBS Journal
Verified
Journal Article
Closed access
PDF file
NNNatalie Ng
Natalie Ng
KPKarin Purshouse
Karin Purshouse
IFIosifina Petrina Foskolou
Iosifina Petrina Foskolou
MOMonica M. Olcina
Monica M. Olcina
EHEsther Hammond
Esther Hammond

25 March 2021 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
ALAlvin Jun Xing Lee
Alvin Jun Xing Lee
KPKarin Purshouse
Karin Purshouse
The SARS-Cov-2 pandemic in 2020 has caused oncology teams around the world to adapt their practice in the aim of protecting patients. Early evidence from China indicated that patients with cancer, and particularly those who had recently received chemotherapy or surgery, were at increased risk of adverse outcomes following SARS-Cov-2 infection. Many registries of cancer patients infected with SARS-Cov-2 emerged during the first wave. We collate the evidence from these national and international studies and focus on the risk factors for patients with solid cancers and the contribution of systemic anti-cancer treatments (SACT—chemotherapy, immunotherapy, targeted and hormone therapy) to outcomes following SARS-Cov-2 infection. Patients with cancer infected with SARS-Cov-2 have a higher probability of death compared with patients without cancer. Common risk factors for mortality following COVID-19 include age, male sex, smoking history, number of comorbidities and poor performance status. Oncological features that may predict for worse outcomes include tumour stage, disease trajectory and lung cancer. Most studies did not identify an association between SACT and adverse outcomes. Recent data suggest that the timing of receipt of SACT may be associated with risk of mortality. Ongoing recruitment to these registries will enable us to provide evidence-based care.

7 December 2022 in eLife
Verified
Journal Article
Open access
KPKarin Purshouse
Karin Purshouse
EFElias T Friman
Elias T Friman
SBShelagh Boyle
Shelagh Boyle
PDPooran Singh Dewari
Pooran Singh Dewari
VGVivien Grant
Vivien Grant
WBWendy A Bickmore
Wendy A Bickmore
Extrachromosomal DNA (ecDNA) are frequently observed in human cancers and are responsible for high levels of oncogene expression. In glioblastoma (GBM), ecDNA copy number correlates with poor prognosis. It is hypothesized that their copy number, size, and chromatin accessibility facilitate clustering of ecDNA and colocalization with transcriptional hubs, and that this underpins their elevated transcriptional activity. Here, we use super-resolution imaging and quantitative image analysis to evaluate GBM stem cells harbouring distinct ecDNA species (EGFR, CDK4, PDGFRA). We find no evidence that ecDNA routinely cluster with one another or closely interact with transcriptional hubs. Cells with EGFR-containing ecDNA have increased EGFR transcriptional output, but transcription per gene copy is similar in ecDNA compared to the endogenous chromosomal locus. These data suggest that it is the increased copy number of oncogene-harbouring ecDNA that primarily drives high levels of oncogene transcription, rather than specific interactions of ecDNA with each other or with high concentrations of the transcriptional machinery.

15 April 2014 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
RSR. Sinha
R. Sinha
KLK. Lecamwasam
K. Lecamwasam
KPK. Purshouse
K. Purshouse
JRJ. Reed
J. Reed
MMM.R. Middleton
M.R. Middleton
LFL. Fearfield
L. Fearfield